Atom Bioworks

Executive Summary

Atom Bioworks is a Cary, NC-based biotechnology company pioneering the use of artificial intelligence to design aptamer-based therapeutics and targeted delivery systems. Founded in 2020, the company's proprietary platform, AptaBLE (Aptamer Binding LanguagE), employs transformer-based machine learning to decode protein-aptamer interactions, enabling rapid generation of high-affinity, nuclease-resistant aptamers against previously undruggable targets. This approach addresses key limitations of traditional aptamer development, such as low affinity and susceptibility to nuclease degradation, potentially unlocking new therapeutic modalities in oncology, inflammation, and other disease areas. As a private, early-stage company with no disclosed funding rounds, Atom Bioworks operates in the competitive AI-driven drug discovery space, distinguishing itself through a focus on aptamers rather than small molecules or antibodies. The company's success hinges on validating its platform through preclinical studies and securing strategic partnerships or venture financing to advance its pipeline toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement60% success
• Q1 2027Preclinical Proof-of-Concept Data for Lead Candidate50% success
• Q2 2027Partnership with Major Pharma for Aptamer Delivery Platform30% success